Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Lopes

Showing results (171-180 of 177) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 177 results.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Clinical Lung Cancer|May 14, 2024
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry AnalysisAmit A Kulkarni, Cassandra Hennessy, Grace Wilson, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
The Lancet. Oncology|May 1, 2013
Planning cancer control in Latin America and the CaribbeanPaul E Goss, Brittany L Lee, Tanja Badovinac-Crnjevic, et al.
Nature Communications|August 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinomaAmin H Nassar, Chul Kim, Tolulope Adeyelu, et al.
Pageof 18

Showing results (171-180 of 177) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 177 results.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Clinical Lung Cancer|May 14, 2024
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry AnalysisAmit A Kulkarni, Cassandra Hennessy, Grace Wilson, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
The Lancet. Oncology|May 1, 2013
Planning cancer control in Latin America and the CaribbeanPaul E Goss, Brittany L Lee, Tanja Badovinac-Crnjevic, et al.
Nature Communications|August 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinomaAmin H Nassar, Chul Kim, Tolulope Adeyelu, et al.
Pageof 18